Ceclazepide is under clinical development by Trio Medicines and currently in Phase I for Reflux Esophagitis (Gastroesophageal Reflux Disease). According to GlobalData, Phase I drugs for Reflux Esophagitis (Gastroesophageal Reflux Disease) have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ceclazepide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ceclazepide (TR-2A) is under development for the treatment of gastro-oesophageal reflux disease, pancreatic cancer, gastric cancer, Barett's oesophagus, and helicobacter pylori Infections. It acts by targeting gastrin/CCK2. It was also under development for gastric neuroendocrine tumors (US and EU).
Trio Medicines overview
Trio Medicines operates in pharmaceutical and healthcare industry. It operates as a subsidiary of Hammersmith Medicines Research Ltd and is headquartered in United Kingdom.
For a complete picture of Ceclazepide’s drug-specific PTSR and LoA scores, buy the report here.